ANCA-associated vasculitis: a new therapeutic area for precision medicine

References

[1] Jennette JC,Bacon PA.2012 revised international chapel hill consensus conference nomenclature of vasculitides.Arthritis Rheum2013;65:1-11

[2] Hilhorst M,Tervaert JW.Limburg Renal RegistryProteinase 3-ANCA vasculitis versus myeloperoxidase-anca vasculitis.J Am Soc Nephrol2015;26:2314-27 PMCID:PMC4587702

[3] Lyons PA,Trivedi S.Genetically distinct subsets within ANCA-associated vasculitis.N Engl J Med2012;367:214-23 PMCID:PMC3773907

[4] Quartuccio L,Valent F.Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases.Intern Emerg Med2021;16:581-9 PMCID:PMC8049888

[5] Geetha D.ANCA-associated vasculitis: core curriculum 2020.Am J Kidney Dis2020;75:124-37

[6] Geetha D,Scott J.Comparisons of guidelines and recommendations on managing antineutrophil cytoplasmic antibody-associated vasculitis.Kidney Int Rep2018;3:1039-49 PMCID:PMC6127414

[7] Jennette JC,Gasim AH.Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis.Curr Opin Nephrol Hypertens2011;20:263-70 PMCID:PMC4096782

[8] Treppo E,Agarinis R,Quartuccio L.Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives.J Clin Med2021;10:3773 PMCID:PMC8432126

[9] Jayne DRW,Schall TJ.ADVOCATE Study GroupAvacopan for the treatment of ANCA-associated vasculitis.N Engl J Med2021;384:599-609

[10] Osman MS.Anti-neutrophil cytoplasmic antibodies (ANCA) as disease activity biomarkers in a "personalized medicine approach" in ANCA-associated vasculitis.Curr Rheumatol Rep2019;21:76